Sulfadiazine silver
Silvadene, Ssd, Thermazene (sulfadiazine, silver) is a small molecule pharmaceutical. Sulfadiazine, silver was first approved as Silvadene on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Silvadene, Ssd, Thermazene (discontinued: Sildaflo, Ssd)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Silver sulfadiazine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SSD | Dr Reddys Laboratories | N-018578 RX | 1982-02-25 | 1 products, RLD, RS |
| SILVADENE | King Pharmaceuticals | N-017381 RX | 1982-01-01 | 1 products, RLD, RS |
| THERMAZENE | The Pharma Network | N-018810 RX | 1985-12-23 | 1 products |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dermazinc | C200263 | 2024-06-06 |
| silvadene | New Drug Application | 2023-12-09 |
| silver sulfadiazene | New Drug Application | 2018-04-19 |
| silver sulfadiazine | New Drug Application | 2024-10-08 |
| ssd | New Drug Application | 2023-06-06 |
| ssd cream | New Drug Application | 2024-10-17 |
| thermazene | New Drug Application | 2024-08-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bacterial infections | — | D001424 | A49 |
| wound infection | — | D014946 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
99 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Burns | D002056 | — | T30.0 | — | 5 | 4 | 6 | 10 | 24 |
| Hearing loss | D034381 | EFO_0004238 | H91.9 | — | — | — | 1 | 12 | 13 |
| Deafness | D003638 | EFO_0001063 | H91.9 | — | — | — | 1 | 12 | 13 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 2 | — | 1 | 4 | 7 |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | 1 | 1 | — | 4 |
| Communicable diseases | D003141 | — | — | 1 | 2 | — | 1 | — | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | — | 1 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | 1 | — | 1 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | — | — | 1 | — | 1 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | — | — | 1 | — | 1 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | 1 | 2 | — | — | 3 |
| Hepatic encephalopathy | D006501 | — | K72.91 | — | 1 | 2 | — | — | 3 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | 1 | — | — | 1 |
| Tibial fractures | D013978 | EFO_0003944 | S82.20 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Radiodermatitis | D011855 | — | L58 | — | 2 | — | — | 2 | 4 |
| Medically unexplained symptoms | D000071896 | — | — | — | 1 | — | — | 3 | 4 |
| Somatoform disorders | D013001 | — | F45 | — | 1 | — | — | 3 | 4 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 2 | — | — | 1 | 3 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | 2 | 3 |
| Colonic neoplasms | D003110 | — | C18 | — | 1 | — | — | 1 | 2 |
| Ulcer | D014456 | MPATH_579 | — | — | 1 | — | — | 1 | 2 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | 1 | — | — | 1 | 2 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | 1 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 1 | 2 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis | D006505 | HP_0012115 | K75.9 | 1 | — | — | — | 1 | 2 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
| Hepatitis b | D006509 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Unilateral hearing loss | D046088 | HP_0009900 | — | — | — | — | — | 7 | 7 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | — | — | 5 | 5 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 5 | 5 |
| Conductive hearing loss | D006314 | HP_0000405 | H90.2 | — | — | — | — | 3 | 3 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 3 | 3 |
| Speech sound disorder | D066229 | — | — | — | — | — | — | 2 | 2 |
| Mixed conductive-sensorineural hearing loss | D046089 | HP_0000410 | H90.8 | — | — | — | — | 2 | 2 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | — | 2 | 2 |
| Leprosy | D007918 | EFO_0001054 | A30 | — | — | — | — | 1 | 1 |
| Anesthesia | D000758 | — | — | — | — | — | — | 1 | 1 |
Show 40 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sulfadiazine silver |
| INN | — |
| Description | Silver(1+) sulfadiazinate is a silver salt, a sulfonamidate and a member of pyrimidines. It has a role as an antimicrobial agent and an antibacterial drug. It contains a sulfadiazinate. |
| Classification | Small molecule |
| Drug class | antimicrobials (sulfonamides derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccc(S(=O)(=O)[N-]c2ncccn2)cc1.[Ag+] |
Identifiers
| PDB | — |
| CAS-ID | 22199-08-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1382627 |
| ChEBI ID | 9142 |
| PubChem CID | 441244 |
| DrugBank | DB05245 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Sulfadiazine silver
+
Silver sulfadiazine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,518 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
863 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use